Powering AI-Driven Drug Discovery with President of Isomorphic Labs Max Jaderberg
Nov 12, 2026 · 39:16
Isomorphic Labs president Max Jaderberg tells Elad Gil that drug discovery must move from empirical trial and error onto computers, using predictive AI models that reach experimental accuracy. AlphaFold was the first proof deep learning could generalize in biology, prompting Isomorphic's 2021 founding. He blames the empirical process for drugs costing $1.5 billion over 15 years with flat approvals, and clinic failures after rat toxicity tests prove only ~30% predictive. Isomorphic generates proprietary data, builds its drug design engine in-house, and focuses on oncology and immunology while partnering with pharma. He argues precise molecule engineering unlocks multidrug cocktails modulating whole pathways and expects predictive disease biology to step-change within five years.